GLOBAL CORD BLOOD overview

Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands (“Grand Court”) on September 22, 2022 (the “Order”) appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton...

Blue Ocean Structure Investment Company Ltd., (“Blue Ocean”) a significant shareholder of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO), today announced the Grand Court of the Cayman Islands (the “Court”) issued an order granting the appointment of joint provisional liquidators (“JPLs”) for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August...

Global Cord Blood Corporation Files Annual Report on Form 20-F PR Newswire HONG KONG, Aug. 17, 2022 HONG KONG , Aug. 17, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes...

Global Cord Blood Corporation Files Annual Report on Form 20-F PR Newswire HONG KONG, Aug. 16, 2022 HONG KONG , Aug. 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes...

Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM PR Newswire HONG KONG, July 6, 2022 HONG KONG , July 6, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that an injunction order (the "Order") previously obtained by the Company on June 15, 2022 from the...

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 PR Newswire HONG KONG, July 5, 2022 Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ( $46.9 Million ) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ( $40.3 Million ) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ( $22.4 Million ) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ( $24.3 Million ) HONG KONG , July...

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 PR Newswire HONG KONG, July 6, 2022 Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ( $46.9 Million ) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ( $40.3 Million ) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ( $22.4 Million ) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ( $24.3 Million ) HONG KONG , July...

Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis PR Newswire HONG KONG, June 16, 2022 HONG KONG , June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announc e that Cellenkos, Inc....